I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Gilloteau, I
58
results:
Search for persons
X
Format
Online (58)
Mediatypes
Articles (Online) (46)
OpenAccess-fulltext (12)
Languages
english (54)
more...
french (1)
russian (1)
less...
Sorted by: Relevance
Sorted by: Year
?
1
PSY19 A COST PER RESPONDER ANALYSIS OF SECUKINUMAB COMPARED..:
Yahiaoui, S.
;
Panguluri, S.
;
MZah, D.
...
Value in Health. 22 (2019) - p. S904-S905 , 2019
Link:
https://doi.org/10.1016/..
?
2
PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLO..:
Mestouri, A.
;
Kooli, A.
;
Bouchaour, N.
.
Value in Health. 22 (2019) - p. S421 , 2019
Link:
https://doi.org/10.1016/..
?
3
Cost‐effectiveness of secukinumab as first biologic treatme..:
Augustin, M.
;
McBride, D.
;
Gilloteau, I.
...
Journal of the European Academy of Dermatology and Venereology. 32 (2018) 12 - p. 2191-2199 , 2018
Link:
https://doi.org/10.1111/..
?
4
Cost Per Responder of Secukinumab Compared to Other Biologi..:
Suzuki, C
;
Lopes, N
;
Tozato, C
..
Value in Health. 21 (2018) - p. S240 , 2018
Link:
https://doi.org/10.1016/..
?
5
A Cost-Per-Responder Analysis of Secukinumab Compared with ..:
Al Howimel, M
;
Al Jufan, K
;
AlAlwan, A
...
Value in Health. 21 (2018) - p. S106 , 2018
Link:
https://doi.org/10.1016/..
?
6
Secukinumab significantly reduces psoriasis‐related work im..:
Warren, R.B.
;
Halliday, A.
;
Graham, C.N.
...
Journal of the European Academy of Dermatology and Venereology. 32 (2018) 12 - p. 2178-2184 , 2018
Link:
https://doi.org/10.1111/..
?
7
PSS31 - COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER..:
Suzuki, C.
;
Lopes, N.
;
Gilloteau, I.
.
Value in Health. 21 (2018) - p. S428 , 2018
Link:
https://doi.org/10.1016/..
?
8
Cost Per-Responder Analysis of Secukinumab Compared to Othe..:
Al Howimel, M
;
Al Jufan, K
;
AlAlwan, A
...
Value in Health. 21 (2018) - p. S106 , 2018
Link:
https://doi.org/10.1016/..
?
9
银屑病负担的多维概述:
Griffiths, C.E.M.
;
Jo, S.-J.
;
Naldi, L.
...
British Journal of Dermatology. 179 (2018) 1 - p. e81-e81 , 2018
Link:
https://doi.org/10.1111/..
?
10
A multidimensional overview of the burden of psoriasis:
Griffiths, C.E.M.
;
Jo, S.-J.
;
Naldi, L.
...
British Journal of Dermatology. 179 (2018) 1 - p. e67-e67 , 2018
Link:
https://doi.org/10.1111/..
?
11
A multidimensional assessment of the burden of psoriasis: r..:
Griffiths, C.E.M.
;
Jo, S.-J.
;
Naldi, L.
...
British Journal of Dermatology. 179 (2018) 1 - p. 173-181 , 2018
Link:
https://doi.org/10.1111/..
?
12
Patient–dermatologist agreement in psoriasis severity, symp..:
Griffiths, C.E.M.
;
Augustin, M.
;
Naldi, L.
...
Journal of the European Academy of Dermatology and Venereology. 32 (2018) 9 - p. 1523-1529 , 2018
Link:
https://doi.org/10.1111/..
?
13
Patient Reported Outcomes in Psoriasis Treatment Decision M..:
Feldman, SR
;
Regnier, SA
;
Gilloteau, I
...
Value in Health. 21 (2018) - p. S242 , 2018
Link:
https://doi.org/10.1016/..
?
14
PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER..:
Bianculli, P.M.
;
Salibe, M.
;
Peirano, I.
..
Value in Health. 21 (2018) - p. S428 , 2018
Link:
https://doi.org/10.1016/..
?
15
PSS41 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED..:
Kooli, A.
;
Graham, C.
;
Scheuer, N.
...
Value in Health. 21 (2018) - p. S429 , 2018
Link:
https://doi.org/10.1016/..
1-15